The inclusion of historical control data may reduce the power of a confirmatory study

Statistics in Medicine

Volumn 30, Issue 12, 2011, Pages 1329-1338

  Cuffe, Robert L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bayes; Clinical trials; Historical data; Power

Indexed keywords

FOSAMPRENAVIR;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL RESEARCH; CONCURRENT CONTROL DATA; DATA ANALYSIS; HISTORICAL CONTROL DATA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; TREATMENT RESPONSE; VALIDITY;

BAYES THEOREM; CARBAMATES; COMPUTER SIMULATION; CONTROL GROUPS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, STATISTICAL; PHOSPHORIC ACID ESTERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; VIRAL LOAD;

EID: 79955824973     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4212     Document Type: Article

References (30)

1. Smith GCS, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327:1459-1461. DOI:10.1136/bmj.327.7429.1459.
2. Temple R. How FDA currently makes decisions on clinical studies. Clinical Trials 2005; 2:276-281.
3. International Conference on Harmonisation. Guidance for Industry E10: Choice of Control Group and Related Issues in Clinical Trials, 2001.
4. Tarone RE. The use of historical control information in testing for a trend in proportions. Biometrics 1982; 38:215-220.
5. Dempster AP, Selwyn MR, Weeks BJ. Combining historical and randomized controls for assessing trends in proportions. Journal of the American Statistical Association 1983; 78:221-227.
6. Kikuchi Y, Tanagawa T. Incorporating historical controls using a random effects model with a normal prior. Communications in Statistics: Theory and Methods 1991; 20:1273-1291. DOI: 10.1080/03610929108830564.
7. van Zwieten MJ, Majka JA, Peter CP, Burek JD. The value of historical control data. In Carcinogenicity: the Design, Analysis and Interpretation of Long-term Animal Studies, Grice HC, Ciminera JL (eds). Springer: New York, 1989; 39-52.
8. Thall PF, Simon R. Incorporating historical control data in planning phase II clinical trials. Statistics in Medicine 1990; 9:215-228. DOI: 10.1002/sim.4780090304.
9. Begg CB, Pilote L. A model for incorporating historical controls into a meta-analysis. Biometrics 1991; 47:899-906.
10. Pocock SJ. The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases 1976; 29:175-188.
11. Ware JH. Investigating therapies of potentially great benefit: ECMO (C/R:P306-340). Statistical Science 1989; 4:298-306.
12. Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006; 295:1264-1273. DOI: 10.1001/jama.295.11.1264.
13. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Wiley: Sussex, 2004.
14. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods (2nd edn). Sage: California, 2002.
15. Carosi G, Lazzarin A, Stellbrink H, Moyle G, Rugina S, Staszewski S, Givens N, Ross L, Granier C, AitKhaled M, Leather D, Nichols WG. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1 infected adult subjects. HIV Clinical Trials 2010; 10:356-367. DOI: 10.1310/hct1006-356.
16. Eron J, Yeni P, Gathe J, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368:476-482. DOI: 10.1016/S0140-6736(06)69155-1.
17. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Wiley: Sussex, 2002.
18. Hardy R, Thompson S. A likelihood approach to meta-analysis with random effects. Statistics in Medicine 1996; 15:619-629.
19. DuMouchel W. Bayesian meta-analysis. Statistical Methodology in the Pharmaceutical Sciences. Marcel Dekker: New York, 1990; 509-529.
20. Daniels MJ. A prior for the variance in hierarchical models. The Canadian Journal of Statistics/La Revue Canadienne de Statistique 1999; 27:567-578.
21. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 2006; 1:515-534. DOI: 10.1214/06-BA117A.
22. Neuenschwander B, Capkun Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clinical Trials 2010. DOI: 10.1177/1740774509356002.
23. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Statistics in Medicine 1999; 18:321-359.
24. Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements, clinical considerations for accelerated and traditional approval. Technical Report, FDA, Silver Spring, MD, 2002.
25. Gould AL. Another view of active-controlled trials. Controlled Clinical Trials 1991; 12:474-485.
26. Ibrahim JG, Chen MH, Sinha D. On optimality properties of the power prior. Journal of the American Statistical Association 2003; 98(461):204-213. DOI: 10.1198/016214503388619229.
27. Eddy DM, Hasselblad V, Shachter R. Meta-Analysis by the Confidence Profile Method: the Statistical Synthesis of Evidence. Academic Press: San Diego, CA, 1992.
28. Fleming TR. Current issues in non-inferiority trials. Statistics in Medicine 2008; 27:317-332. DOI: 10.1002/sim.2855.
29. Berry DA. Bayesian clinical trials. Nature Reviews Drug Discovery 2006; DOI: 10.1038/nrd1927.
30. Hobbs BP, Carlin BP. Practical Bayesian design and analysis for drug and device clinical trials. Journal of Biopharmaceutical Statistics 2008; 18:54-80. DOI: 10.1080/10543400701668266.